Scope and Claims Analysis for US Patent 11,707,456 (Niemann-Pick type C treatment composition, stereochemical impurities, and nitrosamine limits)
US 11,707,456 is a US composition-of-matter and formulation-orientated patent that claims (i) a highly stereochemically defined active ingredient profile (≥98% R-citrate with controlled S-citrate content), (ii) strict low-level impurity control for two specific contaminants including a methyl (Z)-nicotinimidate 1-oxide species and N-nitrosopiperidine, and (iii) oral/form unit dosage embodiments plus method-of-treatment claims for Niemann-Pick disease type C (NPC). The practical claim scope is driven by hard quantitative thresholds (percent stereoisomer content, ppm N-nitrosopiperidine, and percent methyl (Z)-nicotinimidate 1-oxide). Design-around efforts that change formulation excipients or dosage form without changing the claimed impurity profile will not avoid the composition claims; only shifting the active’s impurity/species profile or using different active stereochemistry falls outside the literal claim language.
What is US Patent 11,707,456 claiming at a high level?
Core claim theme: The patent protects a specific drug substance profile and its use in oral dosing for NPC.
Claim 1 defines the drug substance profile (composition-of-matter)
Independent claim 1 is a composition comprising three elements with numeric limits:
- Primary active (R-citrate):
- ≥ 98.0% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate
- Controlled stereoisomer (S-citrate):
- ~1.0% to ~1.9% N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide (or pharmaceutically acceptable salt)
- Low-level methyl nicotinimidate impurity:
- ~0.05% to ~0.1% methyl (Z)—N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide (or salt)
This is not a generic “drug product” claim. It is an API profile claim that hard-codes stereochemical composition and an additional identified impurity/species range.
Claim 2-4 layer nitrosamine control
- Claim 2: pharmaceutical composition wrapper around claim 1.
- Claim 3: includes < 2 ppm N-nitrosopiperidine.
- Claim 4: tightens to ~0.8 to ~2 ppm N-nitrosopiperidine.
This places N-nitrosopiperidine control into the claimed subject matter. If a competing product is the same core active (as defined in claim 1) but has a different N-nitrosopiperidine level outside the claimed bounds, the literal infringement of claim 3/4 may be avoided while still potentially implicating claim 1 (depending on how the product matches the claim 1 impurity set for the methyl nicotinimidate species).
Claims 5-11 cover oral formulation and unit dosage with quantitative dosage and loading
- Claim 5: oral formulation comprising claim 1 composition + excipient(s).
- Claim 6: dosage level 50–500 mg (API dosage basis tied to claim 1 active).
- Claim 7: API loading 20% to 60% w/w of the R-citrate.
- Claim 8: specific unit dosages: 47, 62, 93, 124 mg (R-citrate).
Claims 9-11 mirror the same structure for unit dosage forms.
Claims 12-14 are method-of-treatment claims
- Treat NPC by administering the pharmaceutical composition (claim 2), oral formulation (claim 5), or unit dosage form (claim 9).
Method claims are narrower in that they require administration of a product falling within the upstream composition/formulation claims.
How does Claim 15 change the impurity and nitrosamine profile? (Key independent claim variant)
Independent claim 15 is an alternative drug substance profile claim:
- R-citrate: ≥ 98.0%
- S-citrate: ~1.0% to ~1.9%
- N-nitrosopiperidine: ~0.8 to ~2 ppm (or salt)
Claim 15 does not recite the methyl (Z)-nicotinimidate 1-oxide range. That omission matters for infringement strategy:
- A competitor manufacturing the same stereochemical R/S distribution but controlling N-nitrosopiperidine into the claimed 0.8–2 ppm window will fall within claim 15 even if methyl nicotinimidate impurity is outside the claim 1 range.
- Conversely, a competitor who keeps N-nitrosopiperidine outside 0.8–2 ppm might avoid claim 15 but still could face claim 1 if the methyl nicotinimidate impurity and other conditions match.
Claim 16-18 further lock the methyl nicotinimidate impurity
- Claim 16: pharmaceutical composition wrapper around claim 15.
- Claim 17: methyl (Z)-nicotinimidate 1-oxide < 0.1%
- Claim 18: methyl (Z)-nicotinimidate 1-oxide ~0.05% to ~0.1%.
So the patent has two independent routes to infringement:
- Claim 1 route: R/S + methyl nicotinimidate range (with optional nitrosamine limits in dependent claims 3/4).
- Claim 15 route: R/S + N-nitrosopiperidine range (with optional methyl nicotinimidate limits in dependent claims 17/18).
What specific quantitative limits drive the claim boundaries? (Featured snippet style table)
| Parameter (identified in claims) |
Claim scope location |
Claimed limits (literal) |
Practical infringement consequence |
| R-citrate stereoisomer content |
Claim 1, Claim 15 |
≥ 98.0% |
Any manufacturing that reduces R-citrate below 98.0% can potentially avoid both independent claims. |
| S-citrate stereoisomer content |
Claim 1, Claim 15 |
~1.0% to ~1.9% |
Shifting the S isomer level outside 1.0–1.9% is a key design-around lever. |
| Methyl (Z)—N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide (species) |
Claim 1; Claims 17/18 |
~0.05% to ~0.1% (and <0.1% in claim 17) |
Manufacturing impurity specification must land inside 0.05–0.1% to read on claim 1 and claim 18. |
| N-nitrosopiperidine |
Claim 3/4; Claim 15 |
<2 ppm (claim 3); 0.8–2 ppm (claim 4 and claim 15) |
Nitrosamine control is a second independent boundary. Products outside 0.8–2 ppm may avoid claim 15/4 but not necessarily claim 1 unless methyl impurity also matches. |
| Dosage (per unit) |
Claim 6/10; Claim 8/11 |
50–500 mg; specific 47/62/93/124 mg |
If product’s labeled unit dosing is moved off the enumerated values, unit dosage claims may be harder to assert; composition claims remain unaffected by dosing changes. |
| Formulation loading (w/w) |
Claim 7/21 |
20%–60% |
A composition with the same API profile but outside this loading may avoid oral formulation claims 7/21 while still potentially implicating method claims tied to claim 5/19 depending on how those claims are pleaded. |
Which parts are composition-of-matter vs. formulation vs. method-of-treatment?
Composition-of-matter
- Claim 1: API profile composition (R-citrate ≥98%, S-citrate 1.0–1.9%, methyl nicotinimidate impurity 0.05–0.1%).
- Claim 15: alternative API profile composition (adds N-nitrosopiperidine 0.8–2 ppm).
These claims are the most durable in enforcement because they are not tied to dosage form.
Pharmaceutical composition (composition packaged as drug product)
- Claims 2 and 16 depend from claim 1 and claim 15 respectively.
Oral formulation and unit dosage
- Claims 5-11 (oral formulations and unit dosage forms derived from claim 1).
- Claims 19-25 mirror this structure derived from claim 15.
Method-of-treatment
- Claims 12-14 depend from administered claim 2/5/9.
- Claims 26-28 depend from administered claim 16/19/23.
In litigation, method claims often rise and fall with proof that the administered product meets the upstream product claims.
How broad is the claim scope in practice? (Literal coverage map)
Broadness from composition parameters
The independent claims are broad in that they are not limited to a particular manufacturing route or a particular excipient system. They are pinned to three kinds of specifications:
- stereochemical distribution of the active citrate components
- inclusion of a particular impurity/species at a specific band
- for claim 15, nitrosamine concentration within a defined ppm window.
Narrowness from hard numeric windows
The same specifications also narrow the scope sharply. Literal infringement generally requires:
- R-citrate at least 98.0%,
- S-citrate between ~1.0% and ~1.9%,
- and either:
- methyl nicotinimidate impurity at ~0.05%–0.1% (claim 1) and optionally nitrosamine limits (claims 3/4), or
- N-nitrosopiperidine 0.8–2 ppm (claim 15) and optionally methyl nicotinimidate limits (claims 17/18).
A challenger can focus on moving one controlled attribute outside the band.
Formulation-related narrowness
Oral formulation and unit dosage claims constrain:
- dosage ranges (50–500 mg),
- w/w loading (20%–60%),
- and specific dosage values (47/62/93/124 mg).
These are product-form constraints. Changing strength or formulation loading can weaken those dependent claims without changing the API composition claims.
What is the effective “design-around” surface? (Where competitors can escape literal claim language)
Because the claims are anchored to impurity and stereochemistry thresholds, the most actionable design-around approaches are:
-
Shift stereochemistry out of the claimed windows
- Move R-citrate below 98.0% or S-citrate outside 1.0–1.9%.
-
Shift methyl (Z)-nicotinimidate 1-oxide out of the claimed range
- Keep it below 0.05% or above 0.1% (subject to other constraints and regulatory limits).
-
Shift N-nitrosopiperidine out of 0.8–2 ppm (claim 15/4) or outside <2 ppm (claim 3)
- For example, reduce nitrosamine below 0.8 ppm or elevate above 2 ppm to avoid those claim bands. Whether such a change is feasible while meeting regulatory impurity specs is separate.
-
Strength and formulation changes to escape dependent product claims
- Avoid the enumerated unit dosages (47/62/93/124 mg) and potentially adjust w/w loading outside 20%–60%.
However, any strategy that changes only excipients while keeping the claimed API profile risks leaving composition claims intact.
What does this mean for patent estate coverage in the US? (How 11,707,456 fits claim layers)
Without additional patents or file history details, the only defensible landscape statement is the internal layering inside US 11,707,456 itself:
- Independent API profile protection (claims 1 and 15) is the foundation.
- Dependent nitrosamine and impurity refinement (claims 3/4, 17/18) creates a second tier that can capture products that differ in which impurity specification they meet.
- Dependent formulation and dosing claims (claims 5-11, 19-25) cover oral delivery implementations.
- Method claims (claims 12-14, 26-28) provide usage coverage tied to administration of the claimed products.
This structure is typical for patents that anticipate challenges and attempt to preserve coverage even if one axis of the product profile is argued over.
How are the method-of-treatment claims likely to be asserted?
Method-of-treatment claims (NPC treatment) likely track the clinical product label and prescribed administration. For enforcement, a plaintiff must establish:
- the accused product falls within one of the underlying administered product claims, and
- that administration is for NPC treatment.
The strength of method claims tends to be highest when the accused product is the labeled NPC therapy and the formulation and strength match the claimed dosage and loading.
What formulations are protected by US 11,707,456?
The patent is explicitly limited to oral formulations and unit dosage forms built from the claimed composition. It does not, from the text provided, appear to cover:
- parenteral delivery,
- topical formulations,
- non-oral controlled release systems unless they are still “oral formulations” within the claim scope.
The formulation protections are therefore best read as “oral oral-dosing embodiments with specific strength/load bands.”
What generic entry risks exist based on this claim text alone?
Two risk scenarios flow directly from claim structure:
-
Generic/API profile matching risk
If an ANDA generic or 505(b)(2) applicant uses an API meeting:
- R/S stereochemistry,
- methyl nicotinimidate impurity band (claim 1), and
- optionally N-nitrosopiperidine band (claims 3/4 or claim 15),
then composition and method claims remain at risk.
-
Strength/loading mismatch risk does not eliminate composition exposure
Moving away from 47/62/93/124 mg and altering w/w loading can reduce exposure under claims 7/8/10/11/21/22/24/25. It does not, by itself, eliminate infringement of claims 1 or 15.
Key Takeaways
- US 11,707,456 protects an API profile defined by stereochemistry and specific impurity/species limits:
- Claim 1: R-citrate ≥98.0% + S-citrate 1.0–1.9% + methyl (Z)-nicotinimidate 1-oxide 0.05–0.1%.
- Claim 15: R-citrate ≥98.0% + S-citrate 1.0–1.9% + N-nitrosopiperidine 0.8–2 ppm.
- Dependent claims add tighter impurity bands (nitrosamine and methyl nicotinimidate), creating two overlapping infringement routes.
- Oral formulation and unit dosage claims are constrained by dosage ranges, w/w loading, and specific strength values (47/62/93/124 mg), but they sit on top of the composition claims.
- Method-of-treatment claims for NPC are enforceable to the extent the administered product meets the upstream composition/formulation claims.
- Design-around leverage is strongest at the impurity/stereochemistry level, not only at excipient or strength changes.
FAQs
1) Can a product avoid infringement by changing excipients while keeping the same API profile?
Not if it still matches the claimed composition parameters under claims 1 or 15. Excipient changes do not alter the API stereochemistry and impurity windows.
2) Which impurity matters more for scope: N-nitrosopiperidine or methyl (Z)-nicotinimidate 1-oxide?
Both are central, but they map to different independent routes: methyl (Z)-nicotinimidate is central to claim 1; N-nitrosopiperidine is central to claim 15. Dependent claims then add back the other impurity in narrower bands.
3) If a competitor’s unit strength is not 47/62/93/124 mg, does that fully avoid the patent?
No. Avoiding those specific strengths may reduce coverage under the unit dosage embodiments, but it does not avoid composition claim risk if the API profile matches.
4) Are the method-of-treatment claims independent from the composition claims?
They are dependent in operation on upstream claims because they require administering a pharmaceutical composition/oral formulation/unit dosage form that falls within the claimed categories.
5) What is the most direct way to design around independent claim 1?
Move at least one of the numeric constraints outside its claimed band: R-citrate <98.0%, S-citrate outside 1.0–1.9%, or methyl (Z)-nicotinimidate 1-oxide outside ~0.05%–0.1%.
References
- US Patent 11,707,456.
